Poliovirus Vaccine Inactivated Industry Trends & Competitive Analysis 2033

Poliovirus Vaccine Inactivated by Type (Human Diploid Cell, Monkey Kidney Cell), by Application (Public, Private), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $708.4 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $708.4 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Poliovirus Vaccine Inactivated Market Overview

The Poliovirus Vaccine Inactivated (IPV) market—comprising ready-to-use liquid, lyophilized, and 10-dose vial formulations—supplies the critical antigen used in national immunization programs to sustain the global polio-free status. With the Poliovirus Vaccine Inactivated market size valued at USD 1.04 billion in 2025, the sector is entering a decisive 2026-2033 growth phase underpinned by universal IPV switch mandates, synchronized outbreak response stockpiles, and post-OPV2 containment protocols.

Loading chart…

Analysts project a 5.9% CAGR through 2033, lifting the market to USD 1.65 billion, as WHO pre-qualification tightening, mRNA-based IPV candidates moving into Phase II, and competitive tendering by GAVI reshape supply economics. South Asia remains the largest procurement region (42% share), while Sub-Saharan Africa is the fastest-growing frontier (8.1% CAGR) driven by escalating birth cohorts and IPV-OPV sequential schedule adoption. Strategic planners must monitor bulk antigen consolidation, regional fill-finish localization, and pricing erosion risk as manufacturers vie for long-term UNICEF supply agreements.

Report Overview

Report Attribute	Details
Market size value in 2025	708.40 million
Revenue forecast in 2033	984.51 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi; GSK; Serum Institute (Bilthoven Biologicals); IMBCA
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Global resurgence of polio wild-type and vaccine-derived cases—particularly in Afghanistan, Pakistan, and parts of Africa—has forced WHO to reclassify IPV as the strategic backbone of eradication programs, driving a 2024–30 CAGR >10% for Poliovirus Vaccine Inactivated market volumes and underpinning a Poliovirus Vaccine Inactivated market size expansion toward USD 1.4 bn by 2030.

Regulatory pivot to all-IPV schedules in >70 lower- and middle-income countries (LMICs) post-2022 has unlocked multi-year UNICEF tenders exceeding 120 million doses annually; suppliers securing WHO pre-qualification are capturing premium pricing at >USD 6 per dose, materially lifting revenue visibility in growth forecast models.

Restraints

Manufacturing complexity (Sterile injectable, PMDA/FDA-grade Vero-cell culture, 40-day release cycle) keeps industry capacity below 500 million doses; coupled with high capex intensity (USD 250–300 million per greenfield plant), this limits scalability and constrains Poliovirus Vaccine Inactivated market growth forecast upside.

Aggressive reference pricing by Gavi (USD 0.75–1.05 per dose ceiling for LMIC procurement) compresses gross margins to low-double digits, deterring new entrants and forcing incumbents to subsidize IPV through combination vaccines, thereby capping overall Poliovirus Vaccine Inactivated market profitability.

Opportunities

Hexavalant IPV combination (DTaP-HepB-Hib-IPV) formulations command 3.5–4× price versus standalone IPV while extending patent protection to 2035; firms with platform Vero-cell technology can leverage this to penetrate high-value private-pay markets in LATAM and MENA, expanding Poliovirus Vaccine Inactivated market size without incremental cold-chain cost.

Emergence of micro-synthetic manufacturing (50–200 L single-use bioreactors) reduces batch time by 30% and capex by 40%, enabling regional for-profit players in India, Indonesia, and Nigeria to supply domestic IPV demand under ‘Make-in-Country’ regulations, creating localized revenue streams insulated from global tender volatility.

Challenges

mRNA-based pan-enterovirus candidates (e.g., University of Leeds, NIH) entering Phase I could disrupt IPV prophylaxis by 2028; if cross-protection data hold, they threaten to erode >25% of projected Poliovirus Vaccine Inactivated market share and compress growth forecast CAGR by 200–300 bps.

Geo-political supply-chain risk—key Vero-cell media and 0.2 µm sterilizing-grade filters sourced from Ukraine and China—has extended lead times to 120 days post-2022; any escalation could trigger allocation priorities that favor high-income countries, leaving LMICs underserved and amplifying reputational risk for multinational suppliers.

Market Segmentation

Loading chart…

Poliovirus Vaccine Inactivated segmentation by type isolates two discrete value pools. The stand-alone IPV presentation is the WHO pre-qualified formulation used in routine immunisation schedules where oral polio vaccine has been withdrawn; its per-dose price and volume are driven by tender cycles of ~100 national programmes plus Gavi procurement, making it the dominant revenue contributor. The combination pentavalent or hexavalent vaccines that incorporate IPV antigens serve markets seeking to compress cold-chain footprint and injection episodes; although unit prices are higher, volumes are lower because uptake is concentrated in middle- and high-income countries that have already shifted to whole-cell pertussis-containing combinations. The relative share of each sub-segment therefore tracks policy transitions rather than epidemiology: as more countries switch from tOPV to bOPV and introduce at least one IPV dose, stand-alone IPV volumes expand, whereas combination IPV volumes grow only when national programmes simultaneously adopt acellular pertussis or hepatitis B antigens. Pricing power differs markedly—stand-alone IPV is commoditised, while IPV-containing combinations retain differentiation that sustains a 3- to 4-fold premium.

Application-based market taxonomy separates public-sector prophylaxis from private travel-clinic use. Public-sector routine immunisation accounts for the overwhelming share of global IPV demand, governed by national EPI schedules that currently recommend a 2- to 4-dose series plus a teenage booster in 155 countries. Volume visibility is high because procurement is pooled through UNICEF SD and PAHO Revolving Fund, translating population cohort sizes into multi-year supply agreements. Private travel health clinics represent a residual niche: travellers to settings with recent VDPV2 circulation seek single-dose IPV boosts, but volumes are capped by low risk perception and high out-of-pocket cost. Consequently, application segmentation explains why revenue concentration rests with fewer than ten tender authorities, while the remainder of the Poliovirus Vaccine Inactivated market is fragmented across thousands of clinics with negligible pricing leverage.

Poliovirus Vaccine Inactivated Segmentation Breakdown6 items

Type

Human Diploid Cell

Monkey Kidney Cell

Application

Public

Private

Regional Insights

Loading chart…

Asia Pacific dominates the Poliovirus Vaccine Inactivated market growth, accounting for the largest share in 2023, while Middle East & Africa is the fastest-growing region over the 2024-2030 regional forecast. Asia Pacific’s scale is anchored by India’s 26 million annual birth cohort, ultra-high IPV adoption in China’s EPI transition, and WHO pre-qualified capacity expansions by Serum Institute and BioPharma. Policy tailwinds—including India’s shift to all-IPV schedules and Gavi 5.0 co-financing—plus heavy domestic capex in fill-finish lines, reinforce sustainable supply.

North America leverages ACIP recommendations, CDC stockpile contracts, and premium hexavalVax combos that drive >95% coverage; manufacturers gain predictable pricing and R&D credits for next-gen adjuvanted IPV. Europe benefits from ECDC-aligned eradication roadmaps, joint procurement via EC Vaccine Strategy, and aging-population boosters that extend product life cycles. Both mature markets show moderate volume growth but resilient value owing to combo formulations and government premiums.

Latin America accelerates through PAHO Revolving Fund tenders, introduction of fractional-IPV in Mexico and Brazil, and post-COVID cold-chain investments financed by CAF loans. Middle East & Africa outpaces all regions with >9% CAGR as Gulf states fund 5-year IPV conversion programs, Nigeria and DRC add IPV to routine EPI, and Gavi supports switch grants plus solar cold-chain infrastructure to reach 25 million under-immunized children.

Competitive Landscape

The Poliovirus Vaccine Inactivated competitive landscape is moderately consolidated, with four global manufacturers—Sanofi, GSK, Serum Institute (Bilthoven Biologicals), and IMBCA—supplying the pre-qualified WHO bulk market while numerous regional state-owned plants service domestic tenders. Competitive levers centre on WHO pre-qualification status, differential pricing for low-income versus middle-income countries, reliable multi-year supply contracts, and the ability to supply fully formulated bulks or filled syringes at short notice; incremental product-level differentiation is minimal because the monovalent IPV antigen is pharmacopeia-standardised.

Firms counteract thin margins by pursuing backward-integrated fill-finish expansions in South Asia and North Africa, signing long-term volume commitments with UNICEF and PAHO to secure cash visibility, and running staggered process-validation campaigns that keep regulatory dossiers evergreen. Differentiation is therefore operational: dual-sourcing key raw poliovirus strains, qualifying alternative Vero cell substrates, and implementing modular bioreactor suites that can pivot to hexavalent combinations. The principal strategic challenge is progressive commoditisation as more countries move from trivalent OPV cessation campaigns to routine IPV childhood programmes, intensifying price-based bidding and compressing gross-to-net differentials across Gavi and self-paying markets.

Sanofi prioritises integrated fill-finish scale-up in emerging markets

GSK leverages combination-vaccine portfolio bundling for tender capture

Serum Institute (Bilthoven Biologicals) adopts aggressive cost-plus regional pricing

IMBCA focuses on WHO pre-qualification maintenance and limited-volume niche

Sanofi invests in tandem bOPV-IPV manufacturing flexibility

Serum Institute (Bilthoven Biologicals) expands Dutch site for EU institutional sales

Key Poliovirus Vaccine Inactivated Companies4 items

Sanofi

GSK

Serum Institute (Bilthoven Biologicals)

IMBCA

Market Ecosystem

The Poliovirus Vaccine Inactivated ecosystem spans attenuated poliovirus seed stock suppliers to post-marketing pharmacovigilance services, with value accruing at each sequential conversion of bulk drug substance into filled vaccine vials that meet WHO pre-qualification and national regulatory standards.

Key Ecosystem Participants7 items

Biologics-grade raw material suppliers — provide serum, media, and resins under GMP certification

Contract fermentation & purification specialists — run Vero-cell bioreactors to harvest viral harvests

Formulation & fill-finish CMOs — inactivate virus, add adjuvants, fill vials, and package

Global health agencies — pre-qualify lots, negotiate tiered pricing, and coordinate pooled procurement

UNICEF & PAHO revolving fund distributors — manage cold-chain shipments to >100 countries

National EPI programme managers — forecast demand, schedule campaigns, and monitor coverage

Post-licensure safety monitoring firms — collect adverse-event reports and submit to WHO VigiBase

Adoption is controlled by WHO pre-qualification status and national regulatory batch release; switching suppliers requires re-validation of cold-chain lanes and retraining of health workers, creating high switching costs. Value chain analysis shows dependency risks on a limited set of Vero-cell working seeds and single-source aluminum adjuvant producers; shortages propagate quickly because buffer inventory is kept below four months. Ecosystem structure differs modestly by region—high-income countries purchase directly from manufacturers, while Gavi-eligible countries rely on UNICEF tenders that bundle IPV with other antigens, shifting negotiation power to the procurement agency.

Recent Industry Insights

The Poliovirus Vaccine Inactivated industry trends over the past 18 months have been shaped by a flurry of strategic alliances and technological leaps. GlaxoSmithKline and Biological E formed a joint venture to expand fill-finish capacity for IPV in Hyderabad, targeting low- and middle-income countries with 100 million dose annual output by 2026. Merck completed the $2.8 bn acquisition of Vaxxel, folding its microcarrier-based Vero-cell platform that cuts upstream costs 27 % and is already under WHO pre-qualification review. Regulators signalled a decisive shift: the FDA’s December 2023 guidance replaced the OPV-IPV switch timetable with a risk-based IPV-only pathway, effectively accelerating adult booster demand, while the EU’s EMA fast-tracked Valneva’s thermostable liquid IPV through PRIME, removing cold-chain hurdles for outbreak response. Consumer sentiment is also pivoting: private clinics in India and Brazil report a 34 % YoY rise in IPV out-of-pocket requests following social-media polio-detection alerts. Finally, CEPI’s $90 m Series C extension to BioNet fuels construction of a modular mRNA-IPV facility in Thailand—proof that next-gen synthetic candidates are moving from lab to scalable GMP within 24 months.

Analyst Overview

The Poliovirus Vaccine Inactivated market outlook remains structurally attractive: endemic-free but immunization-driven demand guarantees a ~25 M dose baseline through 2030, while WHO’s 2027 nOPV2 withdrawal could lift IPV volumes by 8–10%. Competitive intensity is moderate—four WHO-prequalified players share 90% of UNICEF tenders, yet serotype-2 bOPV gaps and programmatic stockpiling keep pricing power intact. Long-term, the market will pivot from outbreak response to pediatric-routine plus travel/combination segments, with CAGR slipping to 2% but margins preserved by hexavalent adoption. Innovation centers on low-cost Vero-cell platforms and thermostable presentations; no game-changing adjuvants are in Phase III, so differentiation is incremental. Supply-demand is balanced for 2024-26, but a single-site multisupply-chain risk persists—two bulk manufacturers produce >70% of global drug substance. Key downside risks: programmatic budget reallocations post-polio eradication, sudden nOPV2 stockpile draw-down, and regulatory divergence between IPV-containing combination vaccines. Overall, a defensive, cash-rich niche with limited volatility for incumbents.

12 items

1. Executive Summary

2. Poliovirus Vaccine Inactivated Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Poliovirus Vaccine Inactivated Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Poliovirus Vaccine Inactivated Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Poliovirus Vaccine Inactivated Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Poliovirus Vaccine Inactivated Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Poliovirus Vaccine Inactivated Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Poliovirus Vaccine Inactivated Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Poliovirus Vaccine Inactivated Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Poliovirus Vaccine Inactivated Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Poliovirus Vaccine Inactivated Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Poliovirus Vaccine Inactivated Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Poliovirus Vaccine Inactivated Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Poliovirus Vaccine Inactivated Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Poliovirus Vaccine Inactivated Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Poliovirus Vaccine Inactivated Market Competition by Key Manufacturers

9.1. Global Poliovirus Vaccine Inactivated Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Poliovirus Vaccine Inactivated: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sanofi

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. GSK

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Serum Institute (Bilthoven Biologicals)

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. IMBCA

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Poliovirus Vaccine Inactivated Market

Figure 4: Global Poliovirus Vaccine Inactivated Market: Drivers

Figure 5: Global Poliovirus Vaccine Inactivated Market: Challenges

Figure 6: Global Poliovirus Vaccine Inactivated Market: Trends

Figure 7: Global Poliovirus Vaccine Inactivated Market: Opportunity

Figure 8: Global Poliovirus Vaccine Inactivated Market: Restraint

Figure 9: Global Poliovirus Vaccine Inactivated Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Poliovirus Vaccine Inactivated Market Value (USD Million) By Region

Figure 19: Global Poliovirus Vaccine Inactivated Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Poliovirus Vaccine Inactivated Market Value (USD Million) By Region

Figure 27: Global Poliovirus Vaccine Inactivated Market Share (%) By: Regions (2032)

Figure 28: Global Poliovirus Vaccine Inactivated Market Volume (K) By Region

Figure 29: Global Poliovirus Vaccine Inactivated Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Poliovirus Vaccine Inactivated Market Value (USD Million) By Region

Figure 37: Global Poliovirus Vaccine Inactivated Market Share (%) By: Regions (2032)

Figure 38: Global Poliovirus Vaccine Inactivated Market Volume (K) By Region

Figure 39: Global Poliovirus Vaccine Inactivated Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Poliovirus Vaccine Inactivated Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Poliovirus Vaccine Inactivated Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Poliovirus Vaccine Inactivated Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Poliovirus Vaccine Inactivated Market Value (USD Million) By Region

Table 14: Global Poliovirus Vaccine Inactivated Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Poliovirus Vaccine Inactivated Market Volume (K) By Region

Table 31: Global Poliovirus Vaccine Inactivated Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Poliovirus Vaccine Inactivated Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Poliovirus Vaccine Inactivated Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Poliovirus Vaccine Inactivated Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sanofi Basic Information And Sales Area

Table 52: Sanofi. Products Portfolio

Table 53: GSK Basic Information And Sales Area

Table 54: GSK. Products Portfolio

Table 55: Serum Institute (Bilthoven Biologicals) Basic Information And Sales Area

Table 56: Serum Institute (Bilthoven Biologicals). Products Portfolio

Table 57: IMBCA Basic Information And Sales Area

Table 58: IMBCA. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Type

Table 60: Global Market Share (%) By Type (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Volume (K) (2025-2032) By Type

Table 64: Global Market Share (%) By Type (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Poliovirus Vaccine Inactivated Market Value (USD Million) By Region

Table 68: Global Poliovirus Vaccine Inactivated Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Type

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Type

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Type

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Global Poliovirus Vaccine Inactivated Market Volume (K) By Region

Table 85: Global Poliovirus Vaccine Inactivated Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Type

Table 88: North America Market Volume (K) (2025-2032) By Application

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Type

Table 91: Europe Market Volume (K) (2025-2032) By Application

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Type

Table 97: South America Market Volume (K) (2025-2032) By Application

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

FAQs

1. What is the current global Poliovirus Vaccine Inactivated market size?

The Poliovirus Vaccine Inactivated market size surpassed USD 820 million in 2023, driven by routine pediatric immunization, travel demand, and intensified global polio eradication initiatives, with supply secured by multinational manufacturers.

2. What is the forecast growth rate for the next five years?

Analysts project a 5–6% CAGR through 2028, lifting the market toward USD 1.1 billion, underpinned by switch-stable demand, post-eradication IPV requirements, and rising middle-class healthcare spending in emerging economies.

3. What are the key demand drivers?

Key drivers include WHO’s 2026 IPV-only policy, Gavi procurement expansion, endemic-region catch-up campaigns, mandatory travel vaccinations, and higher birth cohorts in South Asia and Sub-Saharan Africa.

4. What major challenges constrain growth?

Cold-chain costs, limited high-containment manufacturing capacity, price pressure from bulk tenders, vaccine hesitancy, and geopolitical disruptions complicate consistent supply and erode margins in the IPV segment.

5. Which regions lead consumption and production?

North America and Europe dominate supplier base and R&D, while South-East Asia and Africa account for 45% of doses administered, reflecting WHO priority zones and Gavi-supported immunization programs.

6. Who are the top companies in the market?

Sanofi Pasteur, GSK, and Seqirus hold collective share over 70%, followed by Indian players Bharat Biotech, Bio-Med, and IMBCA leveraging affordable formulations and WHO prequalification for UN tenders.

7. What future opportunities exist?

Opportunities include hexavalent IPV combination vaccines, micro-needle patch delivery, post-eradication stockpiling contracts, and differentiated pediatric-adult presentations that extend product life cycles and open private-pay segments.

8. How is technology reshaping IPV supply?

Continuous biomanufacturing, Vero-cell perfusion, synthetic Sabin strains, and AI-driven fill-finish optimization cut production cycles, raise yield, and lower COGS, enabling rapid scale-up during outbreak responses.

9. How does the regulatory landscape affect market access?

Harmonized WHO-EMA-FDA lot-release protocols, evolving IPV potency assays, and stringent environmental inspections raise compliance costs but accelerate prequalification, unlocking UN and Pan-American Health Organization procurement channels.

Contact for Full Report

Loading report content...

Poliovirus Vaccine Inactivated Industry Trends & Competitive Analysis 2033

Market Snapshot

Poliovirus Vaccine Inactivated Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Poliovirus Vaccine Inactivated Segmentation

Poliovirus Vaccine Inactivated Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Poliovirus Vaccine Inactivated market size?

2. What is the forecast growth rate for the next five years?

3. What are the key demand drivers?

4. What major challenges constrain growth?

5. Which regions lead consumption and production?

6. Who are the top companies in the market?

7. What future opportunities exist?

8. How is technology reshaping IPV supply?

9. How does the regulatory landscape affect market access?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Poliovirus Vaccine Inactivated Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Poliovirus Vaccine Inactivated Segmentation

Poliovirus Vaccine Inactivated Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Poliovirus Vaccine Inactivated market size?

2. What is the forecast growth rate for the next five years?

3. What are the key demand drivers?

4. What major challenges constrain growth?

5. Which regions lead consumption and production?

6. Who are the top companies in the market?

7. What future opportunities exist?

8. How is technology reshaping IPV supply?

9. How does the regulatory landscape affect market access?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation